Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070455 | 0.91 | DDB1 (0.55) | DDB1CRBNTRIM24GSK3B | |
| SCHEMBL21069999 | 0.90 | DDB1 (0.56) | DDB1CRBNTRIM24GSK3B | |
| SCHEMBL21071033 | 0.89 | DDB1 (0.59) | DDB1CRBNTRIM24GSK3B | |
| SCHEMBL20850758 | 0.88 | DDB1 (0.62) | DDB1CRBNTRIM24GSK3B | |
| SCHEMBL30299006 | 0.88 | DDB1 (0.62) | DDB1CRBNTRIM24GSK3B | |
| SCHEMBL21069333 | 0.88 | DDB1 (0.62) | DDB1CRBNTRIM24GSK3B | |
| SCHEMBL20845736 | 0.88 | DDB1 (0.62) | DDB1CRBNTRIM24GSK3B | |
| SCHEMBL30042527 | 0.87 | CRBN (0.58) | DDB1CRBNDRD2TRIM24 | |
| SCHEMBL24765162 | 0.87 | CRBN (0.58) | DDB1CRBNDRD2TRIM24 | |
| SCHEMBL21069379 | 0.87 | DDB1 (0.66) | DDB1CRBNGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | DDB1 3837/4885CRBN 183/4885DRD2 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.